Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) EBITDA (2016 - 2025)

Historic EBITDA for KalVista Pharmaceuticals (KALV) over the last 9 years, with Q2 2025 value amounting to -$55.2 million.

  • KalVista Pharmaceuticals' EBITDA fell 2316.47% to -$55.2 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$168.8 million, marking a year-over-year decrease of 8752.03%. This contributed to the annual value of -$185.2 million for FY2025, which is 4572.05% down from last year.
  • According to the latest figures from Q2 2025, KalVista Pharmaceuticals' EBITDA is -$55.2 million, which was down 2316.47% from -$39.8 million recorded in Q3 2024.
  • In the past 5 years, KalVista Pharmaceuticals' EBITDA registered a high of -$28.9 million during Q1 2024, and its lowest value of -$55.2 million during Q2 2025.